Lung Cancer 4e
John Wiley & Sons Inc (Hersteller)
978-1-118-46879-1 (ISBN)
- Keine Verlagsinformationen verfügbar
- Artikel merken
Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease.
Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and authored by leading authorities in the field, this Fourth Edition of the highly regarded Lung Cancer is better than ever -featuring nine new chapters along with seven re-formatted ones that are nearly brand new in content and approach. It covers Smoking Prevention and Cessation; Molecular Profiling; Somatic Genome Alterations in Human Lung Cancers; Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC); Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFR Inhibitors; Non-Small Cell and Small-Cell Lung Carcinoma; and more.
This Fourth Edition of Lung Cancer
Provides the very latest research in the identification of biomarkers to predict a high risk for developing lung cancer - vital for implementing screening, diagnosis, and prevention strategies
Presents the newest lung cancer staging system, as well as updated and cutting-edge surgical and radiation therapy techniques that make local tumor control more effective and less invasive while sparing normal tissues
Discusses combined modality therapy and new chemotherapeutic agents which are yielding higher response rates and improved survival when used in the adjuvant setting or concurrent with highly sophisticated radiation or proton treatment
Offers novel and emergent approaches to preventative, diagnostic, and therapeutic modalities with an emphasis on the best evidence available from the latest studies and clinical trials
With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.
Jack A. Roth , MD, F.A.C.S., is Professor and Bud Johnson Clinical Distinguished Chair in the Department of Thoracic and Cardiovascular Surgery, Professor of Molecular and Cellular Oncology, Director of the W.M. Keck Center of Innovative Cancer Therapies, and Chief of the Section of Thoracic Molecular Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. James D. Cox , MD, is Professor and Head of the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Waun Ki Hong , MD, D.M.Sc. (Hon.), is the American Cancer Society Professor and Samsung Distinguished University Chair in Cancer Medicine, as well as Professor and Head of the Division of Cancer Medicine and Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
Contributors, viii Preface, xiii 1 Smoking Prevention and Cessation, 1 Alexander V. Prokhorov and Karen Suchanek Hudmon 2 Lung Cancer Susceptibility and Risk Assessment Models, 25 Xifeng Wu, Xia Pu, and Jie Lin 3 Molecular Profiling, 48 Lauren Averett Byers 4 Somatic Genome Alterations in Human Lung Cancers, 67 Marcin Imielinski, Peter S. Hammerman, Roman Thomas, and Matthew Meyerson 5 Serum Proteomic Biomarkers, 90 Mohamed Hassanein and David P. Carbone 6 Molecular Biology of Lung Preneoplasia, 110 Humam Kadara and Ignacio I. Wistuba 7 Detection and Treatment of Preneoplastic Lesions, 129 Rachel Jen and Stephen Lam 8 Pathology of Adenocarcinoma, 144 William D. Travis 9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158 Howard West 10 Radiology and Lung Cancer Screening, 176 Patricia de Groot and Reginald F. Munden 11 Imaging Lung Cancer, 191 Sonia L. Betancourt Cuellar, Edith M. Marom, and Jeremy J. Erasmus 12 Staging of the Mediastinum, 202 Mauricio Pipkin and Shaf Keshavjee 13 Management of the Solitary Pulmonary Nodule, 214 Min P. Kim 14 Minimally Invasive Resections for Lung Cancer, 224 Shanda H. Blackmon 15 Extended Resections for Lung Cancer, 236 Matthew A. Steliga and David C. Rice 16 Bronchoscopic Interventions for Lung Cancer, 253 Donald R. Lazarus and George A. Eapen 17 Primary Tracheal Tumors, 267 Francesco Sammartino and Paolo Macchiarini 18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278 Kathryn A. Gold 19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290 Christopher G. Azzoli and Katherine M.W. Pisters 20 Image-Guided Radiation Therapy, 309 Kenneth E. Rosenzweig and Sonal Sura 21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320 Puneeth Iyengar and Robert D. Timmerman 22 Proton Therapy, 338 Joe Y. Chang and James D. Cox 23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353 Daniel Gomez, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki 24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379 Heath D. Skinner, Ritsuko U. Komaki, Joe Y. Chang, and James D. Cox 25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390 Steven H. Lin and Ritsuko U. Komaki 26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406 Kathryn F. Mileham, Edward S. Kim, and William N. William Jr 27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421 Erminia Massarelli 28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435 Lucia Kim, Geoffrey Liu, and Ming-Sound Tsao 29 Immunologic Approaches to Lung Cancer Therapy, 454 Jay M. Lee, Steven M. Dubinett, and Sherven Sharma 30 Novel and Emerging Agents in NSCLC, 464 Anne S. Tsao and Jack A. Roth 31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479 Vassiliki A. Papadimitrakopoulou 32 Novel Statistical Models for NSCLC Clinical Trials, 488 J. Jack Lee and Caleb T. Chu 33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505 John V. Heymach and Tina Cascone 34 Anti-angiogenic Agents in Metastatic NSCLC, 527 Millie Das and Heather Wakelee 35 Targeting ALK Rearrangements, 541 Justin F. Gainor and Alice T. Shaw 36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557 Renata Ferrarotto and George R. Simon 37 Prognostic and Predictive Biomarker Signatures, 564 Johannes R. Kratz and David M. Jablons 38 Brain Metastasis from Lung Cancer, 572 Ritsuko U. Komaki and Amol J. Ghia Index, 591 Color plate section between pages 146 and 147
| Erscheint lt. Verlag | 7.4.2014 |
|---|---|
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 150 x 250 mm |
| Gewicht | 28 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete |
| ISBN-10 | 1-118-46879-1 / 1118468791 |
| ISBN-13 | 978-1-118-46879-1 / 9781118468791 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
